Literature DB >> 15750929

Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study.

Takaharu Oue1, Masami Inoue, Akihiro Yoneda, Akio Kubota, Hiroomi Okuyama, Hisayoshi Kawahara, Masanori Nishikawa, Masahiro Nakayama, Keisei Kawa.   

Abstract

BACKGROUND/
PURPOSE: Neuroblastoma (NB) detected by mass screening (MS) usually shows favorable prognosis and sometimes regresses spontaneously. Therefore, the authors started an observation program for these patients to avoid overtreatment. In this study, the authors analyzed the profile of NB resected after observation to elucidate the nature of NB detected by MS.
METHODS: Between 1994 and 2004, 22 NB patients matched the following criteria and entered the observation program after obtaining informed consent: stage I or II, less than 5 cm in diameter, and without involvement of large vessels or organs. If increase in size, elevation of tumor markers, or evidence of metastasis was observed, the tumor was immediately resected.
RESULTS: Thirteen (59%) of 22 cases showed spontaneous regression. In the remaining 9 cases, tumors were resected because of parents' request, increase in size, and/or elevation of tumor markers. Four tumors had at least one unfavorable biologic feature, and 3 of them had more than 2. According to Shimada's system, 2 had unfavorable histology. One was diploid tumor, 3 had 1p deletion, and Trk-A expression was low in 4 tumors. All patients survived without evidence of recurrence.
CONCLUSIONS: The observation program has shown that at least one third of the NB detected by MS regressed spontaneously. On the other hand, MS may detect some cases with unfavorable tumor in early stage, which benefit from screening.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750929     DOI: 10.1016/j.jpedsurg.2004.10.062

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  10 in total

Review 1.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

2.  Long-term prognosis of low-risk neuroblastoma treated by surgery alone: an experience from a single institution of China.

Authors:  Wei Yao; Kai Li; Kui-Ran Dong; Shan Zheng; Xian-Min Xiao
Journal:  World J Pediatr       Date:  2018-11-16       Impact factor: 2.764

3.  A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.

Authors:  Jed G Nuchtern; Wendy B London; Carol E Barnewolt; Arlene Naranjo; Patrick W McGrady; James D Geiger; Lisa Diller; Mary Lou Schmidt; John M Maris; Susan L Cohn; Robert C Shamberger
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

4.  Neuroblastoma Mass Screening--What Can We Learn From It?

Authors:  Kota Katanoda
Journal:  J Epidemiol       Date:  2016       Impact factor: 3.211

5.  Suprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results.

Authors:  Vassilios Papadakis; Vanessa Segura; Massimo Conte; Dominique Plantaz; Andrea Di Cataldo; Gudrun Schleiermacher; Kate Wheeler; Jose D Bermúdez; Shifra Ash; Bénédicte Brichard; Ruth Ladenstein; Valérie Combaret; Sabine Sarnacki; Anna Maria Fagnani; Claudio Granata; Adela Cañete
Journal:  Cancers (Basel)       Date:  2022-08-19       Impact factor: 6.575

6.  Lysosomal-associated protein multispanning transmembrane 5 gene (LAPTM5) is associated with spontaneous regression of neuroblastomas.

Authors:  Jun Inoue; Akiko Misawa; Yukichi Tanaka; Shizuko Ichinose; Yuriko Sugino; Hajime Hosoi; Tohru Sugimoto; Issei Imoto; Johji Inazawa
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

7.  Incidence of cancer in children residing in ten jurisdictions of the Mexican Republic: importance of the Cancer registry (a population-based study).

Authors:  Arturo Fajardo-Gutiérrez; Servando Juárez-Ocaña; Guadalupe González-Miranda; Virginia Palma-Padilla; Rogelio Carreón-Cruz; Manuel Carlos Ortega-Alvárez; Juan Manuel Mejía-Arangure
Journal:  BMC Cancer       Date:  2007-04-19       Impact factor: 4.430

8.  Epidemiological and some clinical characteristics of neuroblastoma in Mexican children (1996-2005).

Authors:  Servando Juárez-Ocaña; Virginia Palma-Padilla; Guadalupe González-Miranda; Alicia Georgina Siordia-Reyes; Enrique López-Aguilar; Martha Aguilar-Martínez; Juan Manuel Mejía-Aranguré; Rogelio Carreón-Cruz; Mario Enrique Rendón-Macías; Arturo Fajardo-Gutiérrez
Journal:  BMC Cancer       Date:  2009-08-03       Impact factor: 4.430

9.  Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan.

Authors:  Kota Katanoda; Kunihiko Hayashi; Keiko Yamamoto; Tomotaka Sobue
Journal:  J Epidemiol       Date:  2009-08-01       Impact factor: 3.211

10.  Effectiveness of nationwide screening program for neuroblastoma in Japan.

Authors:  Akinori Hisashige
Journal:  Glob J Health Sci       Date:  2014-04-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.